- Investing Ideas
- Swiss Pharmaceuticals & Biotech Healthy high growth potential
Swiss Pharmaceuticals & Biotech Healthy high growth potential
Results
4
Analysts expect these companies to experience strong growth in earnings over the next 3 years. They also meet criteria around being in an acceptable financial position.
4 companies
Kuros Biosciences
Market Cap: CHF 846.0m
Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
KURN
CHF 21.44
7D
12.1%
1Y
-24.2%
SKAN Group
Market Cap: CHF 1.3b
Provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Europe, the Americas, Asia, and internationally.
SKAN
CHF 56.80
7D
-2.7%
1Y
-21.7%
MindMaze Therapeutics Holding
Market Cap: CHF 26.5m
Operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally.
MMTX
CHF 0.17
7D
-16.8%
1Y
n/a
Cosmo
Market Cap: CHF 1.0b
A life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally.
COPN
CHF 64.30
7D
-8.8%
1Y
3.5%